Abstract
To quote from a previous speaker: “at the laboratory level, many examples of useful biochemical modulation have been reported. In contrast to these exciting experimental findings, clinical trials employing biochemical modulation have not clearly demonstrated improvement in the therapeutic indices of the effector agents” (1). This paper will address the problem of the translation of preclinical models of the modulation of FUra metabolism into the clinic. It will be divided into four parts:
-
1.
An introductory section that discusses the essential concepts of biochemical modulation that require translation into the clinic;
-
2.
The identification of those elements, already characterized in preclinical FUra modulation studies;
-
3.
Potential clinical trials that will test the hypothesis of the preclinical FUra modulatory models; and
-
4.
General considerations of translation of biochemical modulation into the clinic.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Martin DS, Stolfi RL, Sawyer RC, Young CW: The application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy. Cancer Treat. Rep. 69: 421–423, 1985.
Ozols RF, Young RC, Myers CE: Phase I pharmacologic studies of adriamycin administered intraperitoneally in patients with ovarian cancer. Cancer Res. 42: 4265–4269, 1982.
Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197: 461–463, 1977.
Hamburger AW, Salmon SE: Primary bioassay of myeloma stem cells. J. Clin. Invest. 60: 846–854, 1977.
Curt GA, Carney DN, Cowan KH et al: Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N. Eng. J. Med. 308: 199–202, 1983.
Ozols RF, Willson JKV, Grotzinger KR et al: Cloning of human ovarian cancer cells in soft agar from malignant effusions and peritoneal washings. Cancer Res. 40: 2743–2747, 1980.
Martin DS, Stolfi RL, Sawyer RC et al: Improved therapeutic index with sequential N-(phosphonacetyl)-L-aspartate + high-dose methotrexate + high-dose 5-fluorouracil and appropriate rescue. Cancer Res. 43: 4653–4661, 1983.
Heidelberger C: Fluorinated pyrimidines and their nucleosides. In: Handbook of Experimental Pharmacology, Vol. 38, Part II, Sartorelli AC, Johns DG (eds), New York, Springer-Verlag, 1975.
Kufe DW, Major PP: 5-fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J. Biol. Chem. 256: 9802–9805, 1981.
Cadman E, Heimer R, Davis L: Enhancement 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism. Science 205: 1135–1137, 1979.
Speigelman S, Sawyer R, Nayak R et al: Improving the antitumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Proc. Natl. Acad. Sci. USA 77: 4966–4970, 1980.
Laskin JD, Evans RM, Slocum HK et al: Basis for natural variation in sensitivity of 5-fluorouracil in mouse and human cells in culture. Cancer Res. 39: 383–398, 1979.
Johnson RK, Inouye T, Goldin A et al: Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. Cancer Res. 36: 2720–2725, 1976.
Martin DS, Stolfi RL, Sawyer RC et al: Significant considerations in the application of biochemical modulation to clinical trials. In press.
Martin DS, Stolfi RL, Sawyer RC et al: Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: A murine study with clinical relevance. Cancer Res. 43: 2317–2321, 1983.
Martin DS, Stolfi RL, Sawyer RC et al: An overview of thymidine. Cancer 45: 1117–1128, 1980.
Moyer JD, Handschumacher RE: Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate. Cancer Res. 39: 3089–3094, 1979.
Yoshida T, Stark GR, Hoogenraad NJ: Inhibition by N-(phosphonacetyl)-L-aspartate of aspartate transcarbamylase activity and drug-induced cell proliferation in mice. J. Biol. Chem. 249: 6951–6955, 1974.
Karle JM, Anderson LW, Dietrick DD, Cysyk RL: Effect of inhibition of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice. Cancer Res. 41: 4952–4955, 1981.
Moore EC, Friedman J, Valdivieso M et al: Aspartate carbamyltransferase activity, drug concentrations, and pyrimidine nucleotides in patients’ tissue after treatment with N-(phosphonacetyl)-L-aspartate (PALA). Biochem. Pharmacol. 31: 3317–3321, 1982.
Kensler TW, Erlichman C, Jayaram HN et al: Peripheral leucocytes as indicators of the enzymatic effects on N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamylase (ATCase) activity. Cancer Treat. Rep. 64: 967–973, 1980.
Loo TL, Friedman J, Moore EC et al: Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans. Cancer Res. 40: 86–90, 1980.
Casper ES, Vale K, Williams LJ et al: Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid. Cancer Res. 2324–2328, 1983.
Mulder JH, Smink T, Van Putten LM: 5-fluorouracil and methotrexate combination chemotherapy: The effect of drug scheduling. Eur. J. Cancer Oncol. 17: 831–837, 1981.
Benz C, Cadman E: Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma, HCT-8. Cancer Res. 41: 994–999, 1981.
Cadman E, Heimer R, Davis L: Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism. Science 205: 1135–1137, 1979.
Coates AS, Tattersal MHN, Swanson C et al: Combination therapy with methotrexate and 5-fluorouracil: A prospective randomized clinical trial of order of administration. J. Clin. Oncol. 2: 756–761, 1984.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Leyland-Jones, B., O’Dwyer, P.J. (1986). Clinical Aspects of FUra Metabolism. In: Valeriote, F.A., Baker, L.H. (eds) Biochemical Modulation of Anticancer Agents: Experimental and Clinical Approaches. Developments in Oncology, vol 47. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2331-0_7
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2331-0_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9432-0
Online ISBN: 978-1-4613-2331-0
eBook Packages: Springer Book Archive